• ExploreBio1

    Positioned to be key player in T-cell engager space

    Read More

  • Pantheon Bioscience

    Positioned to disrupt the molecular tools space

    Read More

  • ExploreBio3

    To be announced in May 2018

    Read More

  • Explore4

    To be announced in July 2018

    Read More

ExploreBio1

Positioned to be key player in T-cell engager space

Location: Yavne, Israel   |   Founded: 2018

Explore Bio I: Newly devised Bi-specific T-Cell engager with dramatically reduced toxicity, having long serum half-life, while maintaining improved tumor penetration.

Linkedin

Oren Bogin, CEO

Dr. Bogin has broad scientific background in the area of protein chemistry with proven track record of scientific leadership, holding various positions both in the Israeli and USA biopharmaceutical industry (ProChon, Alomone, Amunix, Protalix) and and as the Founder and CEO of ChanBio. Dr. Bogin was pivotal is high value collaborations with leading biopharmaceutical companies, establishing the scientific and business goals of these partnership. Dr. Bogin holds a PhD in Chemistry from the Weizmann Institute of Science, where he received the “Dov Elad” prize in Chemistry.
rocket

Pantheon Bioscience

Positioned to disrupt the molecular tools space

Location: Yavne, Israel   |   Founded: 2018

Pantheon Bioscience develops groundbreaking molecular tools based on new anti-phage defense systems discovered by the Professor Rotem Sorek’s lab at the Weizmann Institute of Science. Understanding the mechanisms of action of these new systems will potentially result in disruptive tools for biotechnological applications.

Pantheon Bioscience will be set up in the M Ventures BioIncubator at Inter-Lab, Yavne Israel, profiting from knowledge,expertise and resources.

Linkedin

Professor Rotem Sorek

Scientific Founder

  • Prof. Sorek is a world leader in phage genomics
    and CRISPR research
  • He leads the Microbial Genomics group in
    the Department of Molecular Genetics at the
    Weizmann Institute of Science in Rehovot, Israel
  • Before joining the Weizman Institute, Prof. Sorek
    headed the Genomics Research Group at Compugen Ltd.
  • Accomplished entrepreneur: Scientific founder of BIOMx,
    a microbiome therapeutics company
arrow

Arthur Machlenkin, CEO

12+years of industrial and academic experience in multidisciplinary research and development of novel drugs in immuno-oncology, immunology and oncology. Biotech industry expert in the intersection of drug discovery, target validation and translation research.

Before joining Pantheon Bioscience Arthur served as a principal investigator at Hadassah Medical Center and for the past four years was the Head of Immuno-Oncology Research at Compugen.